小分子抗癌藥物傳輸系統DBPR115

DBPR115, a Novel Small-molecule Drug Conjugate (SMDC)
以小分子胺化合物取代抗體的角色,並與市售的抗腫瘤藥物結合,達到傳遞並集中抗癌藥物到腫瘤組織的功能,有助增加腫瘤中抗癌藥物的濃度,提升抗腫瘤藥效且降低副作用。
DBPR115相較市售藥物CPT-11,僅需20%用藥量即可達到數倍對大腸直腸及胰臟腫瘤生長之抑制效果。
The small molecule amine compound replaces the role of the antibody to combine with commercial tumor drugs to transport and concentrate the cancer drugs in tumor tissues. It effectively increases the cancer drug concentration in tumors to improve the drug effects and reduce side effects. Compared with the commercial drug CPT-11, DBPR115 requires only 20% of the dosage to achieve colorectal, rectal, and pancreatic tumor growth inhibition that is multiple times better.